JXR (01951) announces a profitable year with an estimated profit of no less than 90 million yuan in the first half of the year.

JXR (01951) announces that it expects to achieve the following results for the six months ending on June 30, 2026: (i) Turn the net loss of approximately RMB 1.044 billion in the first half of 2025 into a period profit of not less than RMB 90 million in the first half of 2026; (ii) Achieve an EBITDA (earnings before interest, taxes, depreciation, and amortization) of not less than RMB 290 million, compared to a negative EBITDA of approximately RMB 938.2 million in the first half of 2025; (iii) Achieve an adjusted EBITDA of not less than RMB 300 million, compared to an adjusted EBITDA of approximately RMB 224.7 million in the first half of 2025; (iv) Achieve an adjusted net profit of not less than RMB 120 million, compared to an adjusted net profit of approximately RMB 82.3 million in the first half of 2025. The increases in adjusted EBITDA and adjusted net profit are mainly attributed to: (i) Continued recovery of the group's U.S. business, with an increase in the number of egg retrieval cycles; (ii) Continued expansion of personalized services by the group, driving an increase in the penetration rate of VIP customers; (iii) Further promotion and popularization of reproductive services in China, leading to an overall increase in the number of new infertility patients seeking treatment. The company's turnaround from a net loss to a net profit and from negative EBITDA to positive EBITDA is primarily due to the absence of significant impairment losses and other one-time projects that occurred in the first half of 2025.